

Track record – Diseases – Interventions Transfusion

Blood Component Use in a Sub-Saharan African country: Results of a 4-Year Evaluation of Diagnoses Associated With Transfusion Orders in Namibia. Pitman JP, Wilkinson R, Liu Y, von Finckenstein B, Smit Sibinga CT, Lowrance DW, Marfin AA, Postma MJ, Mataranyika M, Basavaraju SV. *Transfus Med Rev.* 2014 Nov 27. pii: S0887-7963(14)00094-7. doi: 10.1016/j.tmr.2014.11.003. [Epub ahead of print]

The impact of external donor support through the U.S. President's Emergency Plan for AIDS Relief on the cost of red cell concentrate in Namibia, 2004-2011. Pitman JP, Bocking A, Wilkinson R, Postma MJ, Basavaraju SV, Von Finckenstein B, Mataranyika M, Marfin AA, Lowrance DW, Sibinga CT. *Blood Transfus.* 2014 Oct 23:1-8. doi: 10.2450/2014.0122-14. [Epub ahead of print]

Incidence and pattern of 12 years of reported transfusion adverse events in Zimbabwe: a retrospective analysis. Mafirakureva N, Khoza S, Mvere DA, Chitiyo ME, Postma MJ, Van Hulst M. *Blood Transfus.* 2014 Jul;12(3):362-7. doi: 10.2450/2014.0156-13. Epub 2014 Jan 2.

Human immunodeficiency virus prevalence, incidence, and residual transmission risk in first-time and repeat blood donations in Zimbabwe: implications on blood safety. Mapako T, Mvere DA, Chitiyo ME, Rusakaniko S, Postma MJ, van Hulst M. *Transfusion.* 2013 Oct;53(10 Pt 2):2413-21. doi: 10.1111/trf.12311. Epub 2013 Jun 23.

Health economics of blood transfusion safety—focus on sub-Saharan Africa. van Hulst M, Smit Sibinga CT, Postma MJ. *Biologicals.* 2010 Jan;38(1):53-8. doi: 10.1016/j.biologicals.2009.10.006. Epub 2009 Dec 21. Review.

Bedside practice of blood transfusion in a large teaching hospital in Uganda: An observational study. de Graaf JD, Kajja I, Bimenya GS, Postma MJ, Sibinga CT. *Asian J Transfus Sci.* 2009 Jul;3(2):60-5. doi: 10.4103/0973-6247.53872.

Cost-effectiveness of pathogen inactivation for platelet transfusions in the Netherlands. Postma MJ, van Hulst M, De Wolf JT, Botteman M, Staginnus U. *Transfus Med.* 2005 Oct;15(5):379-87.

Cost-effectiveness of leucocyte-depleted erythrocyte transfusion in cardiac valve surgery. van Hulst M, Bilgin YM, van de Watering LM, de Vries R, van Oers MH, Brand A, Postma MJ. *Transfus Med.* 2005 Jun;15(3):209-17.

Cost-effectiveness of transfusion of platelet components prepared with pathogen inactivation treatment in the United States. Bell CE, Botteman MF, Gao X, Weissfeld JL, Postma MJ, Pashos CL, Triulzi D, Staginnus U. *Clin Ther.* 2003 Sep;25(9):2464-86.

Cost-effectiveness of leucocyte depletion of red-cell transfusions for patients undergoing cardiac surgery. Postma MJ, van de Watering LM, de Vries R, Vermoren D, van Hulst M, Tobi H, van der Poel CL, Brand A. *Vox Sang.* 2003 Jan;84(1):65-7. No abstract available.

Pharmaco-economics of blood transfusion safety: review of the available evidence. van Hulst M, de Wolf JT, Staginnus U, Ruitenberg EJ, Postma MJ. *Vox Sang.* 2002 Aug;83(2):146-55. Review.